Literature DB >> 12483715

Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis.

Brad Bolon1, Victoria Shalhoub, Paul J Kostenuik, Giuseppe Campagnuolo, Sean Morony, William J Boyle, Debra Zack, Ulrich Feige.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12483715     DOI： 10.1002/art.10680

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  9 in total

Review 1.  Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.

Authors:  David L Lacey; William J Boyle; W Scott Simonet; Paul J Kostenuik; William C Dougall; John K Sullivan; Javier San Martin; Roger Dansey
Journal:  Nat Rev Drug Discov       Date:  2012-05       Impact factor: 84.694

2.  Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis.

Authors:  Yu Asanuma; Cecilia P Chung; Annette Oeser; Joseph F Solus; Ingrid Avalos; Tebeb Gebretsadik; Ayumi Shintani; Paolo Raggi; Tuulikki Sokka; Theodore Pincus; C Michael Stein
Journal:  Atherosclerosis       Date:  2007-06-14       Impact factor: 5.162

3.  T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis.

Authors:  M C Kraan; J J Haringman; H Weedon; E C Barg; M D Smith; M J Ahern; T J M Smeets; F C Breedveld; P P Tak
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

4.  High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue.

Authors:  Núria Guañabens; Anna Enjuanes; Luisa Alvarez; Pilar Peris; Llorenç Caballería; M Jesús Martínez de Osaba; Dacia Cerdá; Anna Monegal; Francesca Pons; Albert Parés
Journal:  J Bone Miner Metab       Date:  2009-02-20       Impact factor: 2.626

Review 5.  Bone disease in pediatric rheumatologic disorders.

Authors:  Jon M Burnham; Mary B Leonard
Journal:  Curr Rheumatol Rep       Date:  2004-02       Impact factor: 4.592

6.  The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis.

Authors:  Marina Stolina; Brad Bolon; Scot Middleton; Denise Dwyer; Heather Brown; Diane Duryea; Li Zhu; Alison Rohner; James Pretorius; Paul Kostenuik; Ulrich Feige; Debra Zack
Journal:  J Clin Immunol       Date:  2008-08-26       Impact factor: 8.317

Review 7.  Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy.

Authors:  Brad Bolon; Marina Stolina; Caroline King; Scot Middleton; Jill Gasser; Debra Zack; Ulrich Feige
Journal:  J Biomed Biotechnol       Date:  2010-12-28

8.  RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies.

Authors:  Marina Stolina; Georg Schett; Denise Dwyer; Steven Vonderfecht; Scot Middleton; Diane Duryea; Efrain Pacheco; Gwyneth Van; Brad Bolon; Ulrich Feige; Debra Zack; Paul Kostenuik
Journal:  Arthritis Res Ther       Date:  2009-12-11       Impact factor: 5.156

9.  Effect of breastfeeding on serum osteoprotegerin and soluble receptor activator of nuclear factor-kappa B ligand in full term neonates.

Authors:  Mandana Rafeey; Amir Ghorbanihaghjo; Fardad Masoumi; Samira Alizadeh; Sina Davari Farid
Journal:  Iran Red Crescent Med J       Date:  2013-10-05       Impact factor: 0.611
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.